PDCD1 and cancer: By using a newly established autologous in vitro model consisting of functionally impaired PD-1+-T-lymphocytes, three potential Leishmania major (Lm) host cell types and the cancer therapeutic anti-PD-1 antibody nivolumab, we could demonstrate that PD-1 blockade reinvigorated T-cell effector functions.